{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:33:08Z","timestamp":1792549988914,"version":"4.5.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41401-026-01811-y","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T03:15:21Z","timestamp":1779074121000},"page":"2323-2340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cell-based cancer immunotherapy: milestones, mechanistic insights, and emerging therapeutic directions"],"prefix":"10.1038","volume":"47","author":[{"given":"Ji-zhao","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-jun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"1811_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1\u201310.","journal-title":"Immunity"},{"key":"1811_CR2","doi-asserted-by":"crossref","unstructured":"Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res. 1991;(262):3\u201311.","DOI":"10.1097\/00003086-199101000-00002"},{"key":"1811_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/0163-7258(94)90023-X","volume":"64","author":"B Wiemann","year":"1994","unstructured":"Wiemann B, Starnes CO. Coley\u2019s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther. 1994;64:529\u201364.","journal-title":"Pharmacol Ther."},{"key":"1811_CR4","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1126\/science.1840703","volume":"254","author":"P van der Bruggen","year":"1991","unstructured":"van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643\u20137.","journal-title":"Science"},{"key":"1811_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/248701a0","volume":"248","author":"RM Zinkernagel","year":"1974","unstructured":"Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature. 1974;248:701\u20132.","journal-title":"Nature"},{"key":"1811_CR6","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A Preliminary Rep N Engl J Med. 1988;319:1676\u201380.","journal-title":"A Preliminary Rep N Engl J Med"},{"key":"1811_CR7","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126\u20139.","journal-title":"Science"},{"key":"1811_CR8","first-page":"595","volume":"75","author":"S Rosenberg","year":"1985","unstructured":"Rosenberg S. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst. 1985;75:595\u2013603.","journal-title":"J Natl Cancer Inst"},{"key":"1811_CR9","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989;86:10024\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1811_CR10","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993;90:720\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1811_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"1811_CR12","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"1811_CR13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"1811_CR14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382:545\u201353.","journal-title":"N Engl J Med"},{"key":"1811_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411\u201322.","journal-title":"N Engl J Med"},{"key":"1811_CR16","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38:947\u201353.","journal-title":"Nat Biotechnol"},{"key":"1811_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u201350.","journal-title":"Nat Med"},{"key":"1811_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1811_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367:eaba7365.","journal-title":"Science"},{"key":"1811_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj2013","volume":"9","author":"W Qasim","year":"2017","unstructured":"Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017;9:eaaj2013.","journal-title":"Sci Transl Med"},{"key":"1811_CR21","doi-asserted-by":"publisher","first-page":"e505","DOI":"10.1016\/S2352-3026(25)00142-5","volume":"12","author":"P Strati","year":"2025","unstructured":"Strati P, Castro J, Goodman A, Bachanova V, Kamdar M, Awan FT, et al. Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study. Lancet Haematol. 2025;12:e505\u201315.","journal-title":"Lancet Haematol"},{"key":"1811_CR22","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du B, Qin J, Lin B, Zhang J, Li D, Liu M. CAR-T therapy in solid tumors. Cancer Cell. 2025;43:665\u201379.","journal-title":"Cancer Cell"},{"key":"1811_CR23","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1016\/j.ymthe.2020.07.023","volume":"28","author":"AC Boroughs","year":"2020","unstructured":"Boroughs AC, Larson RC, Marjanovic ND, Gosik K, Castano AP, Porter CBM, et al. A distinct transcriptional program in human CAR T cells bearing the 4-1BB signaling domain revealed by scRNA-Seq. Mol Ther. 2020;28:2577\u201392.","journal-title":"Mol Ther"},{"key":"1811_CR24","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581\u201390.","journal-title":"Nat Med"},{"key":"1811_CR25","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","volume":"33","author":"J Chen","year":"2023","unstructured":"Chen J, Qiu S, Li W, Wang K, Zhang Y, Yang H, et al. Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness. Cell Res. 2023;33:341\u201354.","journal-title":"Cell Res"},{"key":"1811_CR26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s11684-025-1130-x","volume":"19","author":"Y Huang","year":"2025","unstructured":"Huang Y, Wang H. Tonic signaling in CAR-T therapy: the lever long enough to move the planet. Front Med. 2025;19:391\u2013408.","journal-title":"Front Med"},{"key":"1811_CR27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn RC, Weber EW, Sotillo E, Gennert D, Xu P, Good Z, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature. 2019;576:293\u2013300.","journal-title":"Nature"},{"key":"1811_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature. 2017;543:113\u20137.","journal-title":"Nature"},{"key":"1811_CR29","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1200\/JCO.23.02786","volume":"42","author":"MD Jain","year":"2024","unstructured":"Jain MD, Spiegel JY, Nastoupil LJ, Tamaresis J, Ghobadi A, Lin Y, et al. Five-year follow-up of standard-of-care axicabtagene ciloleucel for large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2024;42:3581\u201392.","journal-title":"J Clin Oncol"},{"key":"1811_CR30","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282\u201395.","journal-title":"Cancer Discov"},{"key":"1811_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1165870","volume":"14","author":"C Aparicio-P\u00e9rez","year":"2023","unstructured":"Aparicio-P\u00e9rez C, Carmona M, Benabdellah K, Herrera C. Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL. Front Immunol. 2023;14:1165870.","journal-title":"Front Immunol"},{"key":"1811_CR32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:563\u201371.","journal-title":"Nat Med"},{"key":"1811_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/14737140.2024.2421194","volume":"25","author":"N Mobark","year":"2025","unstructured":"Mobark N, Hull CM, Maher J. Optimising CAR T therapy for the treatment of solid tumors. Expert Rev Anticancer Ther. 2025;25:9\u201325.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1811_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","volume":"22","author":"NE Scharping","year":"2021","unstructured":"Scharping NE, Rivadeneira DB, Menk AV, Vignali PDA, Ford BR, Rittenhouse NL, et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol. 2021;22:205\u201315.","journal-title":"Nat Immunol"},{"key":"1811_CR35","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843\u201351.","journal-title":"Mol Ther"},{"key":"1811_CR36","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375:2561\u20139.","journal-title":"N Engl J Med"},{"key":"1811_CR37","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28:1189\u201398.","journal-title":"Nat Med"},{"key":"1811_CR38","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1038\/s41591-025-03874-6","volume":"31","author":"F Locatelli","year":"2025","unstructured":"Locatelli F, Pagliara D, De Ioris MA, Becilli M, Del Baldo G, Serra A, et al. GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1\/2 trial. Nat Med. 2025;31:3689\u201399.","journal-title":"Nat Med"},{"key":"1811_CR39","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1007\/s00277-025-06467-y","volume":"104","author":"X Wang","year":"2025","unstructured":"Wang X, He X, Zhang T, Liu J, Zhao M. Latest updates on pathogenesis mechanisms and management strategies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis related to CAR-T cell therapies. Ann Hematol. 2025;104:3129\u201351.","journal-title":"Ann Hematol"},{"key":"1811_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00281-024-01013-w","volume":"46","author":"AD Hughes","year":"2024","unstructured":"Hughes AD, Teachey DT, Diorio C. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy. Semin Immunopathol. 2024;46:5.","journal-title":"Semin Immunopathol"},{"key":"1811_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40164-025-00638-3","volume":"14","author":"V Gal\u00e1n-G\u00f3mez","year":"2025","unstructured":"Gal\u00e1n-G\u00f3mez V, Gonz\u00e1lez-Mart\u00ednez B, Alonso-Saladrigues A, Rives S, Herrero B, Kwon M, et al. Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults. Exp Hematol Oncol. 2025;14:49.","journal-title":"Exp Hematol Oncol"},{"key":"1811_CR42","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","volume":"25","author":"I Diaconu","year":"2017","unstructured":"Diaconu I, Ballard B, Zhang M, Chen Y, West J, Dotti G, et al. Inducible caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells. Mol Ther. 2017;25:580\u201392.","journal-title":"Mol Ther"},{"key":"1811_CR43","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/s41571-025-01075-1","volume":"22","author":"J Li","year":"2025","unstructured":"Li J, Liu C, Zhang P, Shen L, Qi C. Optimizing CAR T cell therapy for solid tumours: a clinical perspective. Nat Rev Clin Oncol. 2025;22:953\u201368.","journal-title":"Nat Rev Clin Oncol"},{"key":"1811_CR44","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1002\/ijc.34635","volume":"153","author":"S Stock","year":"2023","unstructured":"Stock S, Kl\u00fcver AK, Fertig L, Menkhoff VD, Subklewe M, Endres S, et al. Mechanisms and strategies for safe chimeric antigen receptor T-cell activity control. Int J Cancer. 2023;153:1706\u201325.","journal-title":"Int J Cancer"},{"key":"1811_CR45","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41422-024-00936-1","volume":"34","author":"S Qiu","year":"2024","unstructured":"Qiu S, Chen J, Wu T, Li L, Wang G, Wu H, et al. CAR-Toner: an AI-driven approach for CAR tonic signaling prediction and optimization. Cell Res. 2024;34:386\u20138.","journal-title":"Cell Res"},{"key":"1811_CR46","doi-asserted-by":"publisher","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","volume":"113","author":"LV Hurton","year":"2016","unstructured":"Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, Maiti S, et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci USA. 2016;113:E7788\u2013e97.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1811_CR47","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12026-025-09687-6","volume":"73","author":"T Premchandani","year":"2025","unstructured":"Premchandani T, Qutub M, Tatode A, Umekar M, Taksande J, Hussain UM, et al. Engineering CAR-T cells for solid tumors: bispecific antigen targeting, tumor microenvironment modulation, and toxicity control. Immunol Res. 2025;73:135.","journal-title":"Immunol Res"},{"key":"1811_CR48","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.184545","volume":"10","author":"DA Schoenfeld","year":"2024","unstructured":"Schoenfeld DA, Djureinovic D, Su DG, Zhang L, Lu BY, Kamga L, et al. Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma. JCI Insight. 2024;10:e184545.","journal-title":"JCI Insight"},{"key":"1811_CR49","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/intimm\/dxad033","volume":"36","author":"Y Kagoya","year":"2024","unstructured":"Kagoya Y. Cytokine signaling in chimeric antigen receptor T-cell therapy. Int Immunol. 2024;36:49\u201356.","journal-title":"Int Immunol"},{"key":"1811_CR50","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-022-04801-2","volume":"607","author":"A Kalbasi","year":"2022","unstructured":"Kalbasi A, Siurala M, Su LL, Tariveranmoshabad M, Picton LK, Ravikumar P, et al. Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature. 2022;607:360\u20135.","journal-title":"Nature"},{"key":"1811_CR51","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41590-021-00940-2","volume":"22","author":"Y Guo","year":"2021","unstructured":"Guo Y, Xie YQ, Gao M, Zhao Y, Franco F, Wenes M, et al. Metabolic reprogramming of terminally exhausted CD8(+) T cells by IL-10 enhances anti-tumor immunity. Nat Immunol. 2021;22:746\u201356.","journal-title":"Nat Immunol"},{"key":"1811_CR52","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41375-020-0874-1","volume":"35","author":"X Li","year":"2021","unstructured":"Li X, Daniyan AF, Lopez AV, Purdon TJ, Brentjens RJ. Cytokine IL-36\u03b3 improves CAR T-cell functionality and induces endogenous antitumor response. Leukemia. 2021;35:506\u201321.","journal-title":"Leukemia"},{"key":"1811_CR53","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185\u201399.","journal-title":"Nat Rev Drug Discov"},{"key":"1811_CR54","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L, et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell. 2024;187:4890\u2013904.e9.","journal-title":"Cell"},{"key":"1811_CR55","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1016\/j.cell.2025.05.038","volume":"188","author":"X Wang","year":"2025","unstructured":"Wang X, Zhang Y, Jin Y, Dai L, Yue Y, Hu J, et al. An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis. Cell. 2025;188:4225\u201338.e12.","journal-title":"Cell"},{"key":"1811_CR56","doi-asserted-by":"publisher","first-page":"4953","DOI":"10.1016\/j.ymthe.2025.07.006","volume":"33","author":"T Coradin","year":"2025","unstructured":"Coradin T, Keating AL, Barnard AR, Whilding L, Pombal D, Hannoun Z, et al. Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector. Mol Ther. 2025;33:4953\u201367.","journal-title":"Mol Ther"},{"key":"1811_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202304378","volume":"20","author":"MM Billingsley","year":"2024","unstructured":"Billingsley MM, Gong N, Mukalel AJ, Thatte AS, El-Mayta R, Patel SK, et al. In Vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small. 2024;20:e2304378.","journal-title":"Small"},{"key":"1811_CR58","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365:1673\u201383.","journal-title":"N Engl J Med"},{"key":"1811_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.835762","volume":"13","author":"P Shafer","year":"2022","unstructured":"Shafer P, Kelly LM, Hoyos V. Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects. Front Immunol. 2022;13:835762.","journal-title":"Front Immunol."},{"key":"1811_CR60","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1200\/JCO.18.02424","volume":"37","author":"SL Doran","year":"2019","unstructured":"Doran SL, Stevanovi\u0107 S, Adhikary S, Gartner JJ, Jia L, Kwong MLM, et al. T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I\/II study. J Clin Oncol. 2019;37:2759\u201368.","journal-title":"J Clin Oncol"},{"key":"1811_CR61","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","volume":"25","author":"AG Chapuis","year":"2019","unstructured":"Chapuis AG, Egan DN, Bar M, Schmitt TM, McAfee MS, Paulson KG, et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat Med. 2019;25:1064\u201372.","journal-title":"Nat Med"},{"key":"1811_CR62","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","volume":"8","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J, Kaplan R, et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259)T cells in synovial sarcoma. Cancer Discov. 2018;8:944\u201357.","journal-title":"Cancer Discov"},{"key":"1811_CR63","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","volume":"403","author":"SP D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay JY, et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024;403:1460\u201371.","journal-title":"Lancet"},{"key":"1811_CR64","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1002\/cam4.3039","volume":"9","author":"SM Pollack","year":"2020","unstructured":"Pollack SM, Somaiah N, Araujo DM, Druta M, Van Tine BA, Burgess MA, et al. Clinical outcomes of patients with advanced synovial sarcoma or myxoid\/round cell liposarcoma treated at major cancer centers in the United States. Cancer Med. 2020;9:4593\u2013602.","journal-title":"Cancer Med"},{"key":"1811_CR65","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","volume":"28","author":"J Wagner","year":"2020","unstructured":"Wagner J, Wickman E, DeRenzo C, Gottschalk S. CAR T cell therapy for solid tumors: bright future or dark reality? Mol Ther. 2020;28:2320\u201339.","journal-title":"Mol Ther"},{"key":"1811_CR66","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","volume":"36","author":"RA Morgan","year":"2013","unstructured":"Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013;36:133\u201351.","journal-title":"J Immunother"},{"key":"1811_CR67","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1136\/gutjnl-2025-335456","volume":"75","author":"X Wu","year":"2025","unstructured":"Wu X, Quan D, Li W, Wisskirchen K, Wu W, Zhou Y, et al. Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial. Gut. 2025;75:147\u201360.","journal-title":"Gut"},{"key":"1811_CR68","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1158\/1078-0432.CCR-25-0595","volume":"31","author":"KK Barnett","year":"2025","unstructured":"Barnett KK, Johnson AR, Das A, Lee CJ, Wang C, Wang X, et al. FDA approval summary: afamitresgene autoleucel for adults with HLA-restricted, MAGE-A4-positive unresectable or metastatic synovial sarcoma after prior chemotherapy. Clin Cancer Res. 2025;31:3112\u20137.","journal-title":"Clin Cancer Res"},{"key":"1811_CR69","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114:535\u201346.","journal-title":"Blood"},{"key":"1811_CR70","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122:863\u201371.","journal-title":"Blood"},{"key":"1811_CR71","doi-asserted-by":"publisher","first-page":"197ra03","DOI":"10.1126\/scitranslmed.3006034","volume":"5","author":"BJ Cameron","year":"2013","unstructured":"Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013;5:197ra03.","journal-title":"Sci Transl Med"},{"key":"1811_CR72","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nm.2700","volume":"18","author":"E Provasi","year":"2012","unstructured":"Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med. 2012;18:807\u201315.","journal-title":"Nat Med"},{"key":"1811_CR73","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","volume":"559","author":"TL Roth","year":"2018","unstructured":"Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature. 2018;559:405\u20139.","journal-title":"Nature"},{"key":"1811_CR74","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","volume":"386","author":"R Leidner","year":"2022","unstructured":"Leidner R, Sanjuan Silva N, Huang H, Sprott D, Zheng C, Shih YP, et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N Engl J Med. 2022;386:2112\u20139.","journal-title":"N Engl J Med"},{"key":"1811_CR75","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","volume":"23","author":"ME Dudley","year":"2005","unstructured":"Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346\u201357.","journal-title":"J Clin Oncol"},{"key":"1811_CR76","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s40425-018-0391-1","volume":"6","author":"MW Rohaan","year":"2018","unstructured":"Rohaan MW, van den Berg JH, Kvistborg P, Haanen J. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option. J Immunother Cancer. 2018;6:102.","journal-title":"J Immunother Cancer"},{"key":"1811_CR77","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","volume":"39","author":"AA Sarnaik","year":"2021","unstructured":"Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol. 2021;39:2656\u201366.","journal-title":"J Clin Oncol"},{"key":"1811_CR78","doi-asserted-by":"publisher","first-page":"e005755","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"J Chesney","year":"2022","unstructured":"Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022;10:e005755.","journal-title":"J Immunother Cancer"},{"key":"1811_CR79","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"Rohaan","year":"2022","unstructured":"Rohaan, Borch MW, van den Berg TH, Met \u00d6 JH, Kessels R, Geukes Foppen MH, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med. 2022;387:2113\u201325.","journal-title":"N Engl J Med"},{"key":"1811_CR80","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1158\/1078-0432.CCR-25-0880","volume":"31","author":"L Hu","year":"2025","unstructured":"Hu L, Fan C, Bross P, Das A, Cho ES, Knudson KM, et al. FDA approval summary: lifileucel for unresectable or metastatic melanoma previously treated with an anti-PD-1-based immunotherapy. Clin Cancer Res. 2025;31:4004\u20139.","journal-title":"Clin Cancer Res"},{"key":"1811_CR81","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s10147-025-02699-0","volume":"30","author":"A Ogasawara","year":"2025","unstructured":"Ogasawara A, Hasegawa K. Recent advances in immunotherapy for cervical cancer. Int J Clin Oncol. 2025;30:434\u201348.","journal-title":"Int J Clin Oncol"},{"key":"1811_CR82","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","volume":"33","author":"S Stevanovi\u0107","year":"2015","unstructured":"Stevanovi\u0107 S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015;33:1543\u201350.","journal-title":"J Clin Oncol"},{"key":"1811_CR83","doi-asserted-by":"publisher","first-page":"e011633","DOI":"10.1136\/jitc-2025-011633","volume":"13","author":"RM Ferris","year":"2025","unstructured":"Ferris RM, Leidner RS, Chung CH, Jimeno A, Lee SM, Sukari A, et al. Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma. J Immunother Cancer. 2025;13:e011633.","journal-title":"J Immunother Cancer"},{"key":"1811_CR84","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1158\/2159-8290.CD-23-1334","volume":"14","author":"AJ Schoenfeld","year":"2024","unstructured":"Schoenfeld AJ, Lee SM, Doger de Sp\u00e9ville B, Gettinger SN, H\u00e4fliger S, Sukari A, et al. Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non-small cell lung cancer resistant to immune checkpoint inhibitors. Cancer Discov. 2024;14:1389\u2013402.","journal-title":"Cancer Discov"},{"key":"1811_CR85","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","volume":"15","author":"S Anguille","year":"2014","unstructured":"Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014;15:e257\u201367.","journal-title":"Lancet Oncol"},{"key":"1811_CR86","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","volume":"9","author":"LM Liau","year":"2023","unstructured":"Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol. 2023;9:112\u201321.","journal-title":"JAMA Oncol"},{"key":"1811_CR87","doi-asserted-by":"publisher","first-page":"368ra171","DOI":"10.1126\/scitranslmed.aag1298","volume":"8","author":"J Rosenblatt","year":"2016","unstructured":"Rosenblatt J, Stone RM, Uhl L, Neuberg D, Joyce R, Levine JD, et al. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016;8:368ra171.","journal-title":"Sci Transl Med"},{"key":"1811_CR88","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00262-018-2198-9","volume":"67","author":"AA van de Loosdrecht","year":"2018","unstructured":"van de Loosdrecht AA, van Wetering S, Santegoets S, Singh SK, Eeltink CM, den Hartog Y, et al. A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia. Cancer Immunol Immunother. 2018;67:1505\u201318.","journal-title":"Cancer Immunol Immunother"},{"key":"1811_CR89","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2010-04-277137","volume":"117","author":"J Rosenblatt","year":"2011","unstructured":"Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, et al. Vaccination with dendritic cell\/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011;117:393\u2013402.","journal-title":"Blood"},{"key":"1811_CR90","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41586-018-0433-3","volume":"561","author":"P Zhou","year":"2018","unstructured":"Zhou P, She Y, Dong N, Li P, He H, Borio A, et al. Alpha-kinase 1 is a cytosolic innate immune receptor for bacterial ADP-heptose. Nature. 2018;561:122\u20136.","journal-title":"Nature"},{"key":"1811_CR91","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41586-025-08758-w","volume":"641","author":"X Wang","year":"2025","unstructured":"Wang X, Huang Z, Xing L, Shang L, Jiang J, Deng C, et al. STING agonist-based ER-targeting molecules boost antigen cross-presentation. Nature. 2025;641:202\u201310.","journal-title":"Nature"},{"key":"1811_CR92","doi-asserted-by":"publisher","DOI":"10.1172\/JCI180622","volume":"135","author":"H Zhang","year":"2025","unstructured":"Zhang H, Wang Z, Wu J, Zheng YQ, Zhao Q, He S, et al. Endothelial STING-JAK1 interaction promotes tumor vasculature normalization and antitumor immunity. J Clin Invest. 2025;135:e180622.","journal-title":"J Clin Invest"},{"key":"1811_CR93","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","volume":"405","author":"A Ghobadi","year":"2025","unstructured":"Ghobadi A, Bachanova V, Patel K, Park JH, Flinn I, Riedell PA, et al. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet. 2025;405:127\u201336.","journal-title":"Lancet"},{"key":"1811_CR94","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","volume":"8","author":"R Romee","year":"2016","unstructured":"Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8:357ra123.","journal-title":"Sci Transl Med"},{"key":"1811_CR95","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade3341","volume":"15","author":"F Cichocki","year":"2023","unstructured":"Cichocki F, Zhang B, Wu CY, Chiu E, Day A, O\u2019Connor RS, et al. Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma. Sci Transl Med. 2023;15:eade3341.","journal-title":"Sci Transl Med"},{"key":"1811_CR96","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial. Nat Med. 2024;30:772\u201384.","journal-title":"Nat Med."},{"key":"1811_CR97","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.3390\/biomedicines13082012","volume":"13","author":"X Xun","year":"2025","unstructured":"Xun X, Hao J, Cheng Q, Gao P. Induced pluripotent stem cell-based cancer immunotherapy: strategies and perspectives. Biomedicines. 2025;13:2012.","journal-title":"Biomedicines"},{"key":"1811_CR98","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1158\/1078-0432.CCR-25-0197","volume":"31","author":"AN Courtney","year":"2025","unstructured":"Courtney AN, Zhou X, Tian G, Wang Y, Metelitsa LS, Dotti G. Facts and hopes of chimeric antigen receptor-redirected NK T cells. Clin Cancer Res. 2025;31:5137\u201344.","journal-title":"Clin Cancer Res"},{"key":"1811_CR99","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","volume":"43","author":"YR Li","year":"2025","unstructured":"Li YR, Zhou Y, Yu J, Kim YJ, Li M, Lee D, et al. Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat Biotechnol. 2025;43:329\u201344.","journal-title":"Nat Biotechnol"},{"key":"1811_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100804","volume":"6","author":"YR Li","year":"2025","unstructured":"Li YR, Li Z, Zhu Y, Li M, Chen Y, Lee D, et al. Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Med. 2025;6:100804.","journal-title":"Med"},{"key":"1811_CR101","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2517786122","volume":"122","author":"YR Li","year":"2025","unstructured":"Li YR, Shen X, Zhu E, Li Z, Huang J, Le T, et al. Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell-engineered mesothelin-redirected CAR-NKT cells. Proc Natl Acad Sci USA. 2025;122:e2517786122.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1811_CR102","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","volume":"31","author":"Y Nieto","year":"2025","unstructured":"Nieto Y, Banerjee P, Kaur I, Basar R, Li Y, Daher M, et al. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase\u20091 trial. Nat Med. 2025;31:1987\u201393.","journal-title":"Nat Med"},{"key":"1811_CR103","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1158\/2326-6066.CIR-21-1052","volume":"10","author":"F Souza-Fonseca-Guimaraes","year":"2022","unstructured":"Souza-Fonseca-Guimaraes F, Rossi GR, Dagley LF, Foroutan M, McCulloch TR, Yousef J, et al. TGF\u03b2 and CIS inhibition overcomes NK-cell suppression to restore antitumor immunity. Cancer Immunol Res. 2022;10:1047\u201354.","journal-title":"Cancer Immunol Res"},{"key":"1811_CR104","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/0008-5472.CAN-17-2826","volume":"78","author":"A Young","year":"2018","unstructured":"Young A, Ngiow SF, Gao Y, Patch AM, Barkauskas DS, Messaoudene M, et al. A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment. Cancer Res. 2018;78:1003\u201316.","journal-title":"Cancer Res"},{"key":"1811_CR105","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1016\/j.ymthe.2024.06.034","volume":"32","author":"Y Gong","year":"2024","unstructured":"Gong Y, Germeraad WTV, Zhang X, Wu N, Li B, Janssen L, et al. NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody. Mol Ther. 2024;32:2711\u201327.","journal-title":"Mol Ther"},{"key":"1811_CR106","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.it.2022.04.008","volume":"43","author":"RY Ma","year":"2022","unstructured":"Ma RY, Black A, Qian BZ. Macrophage diversity in cancer revisited in the era of single-cell omics. Trends Immunol. 2022;43:546\u201363.","journal-title":"Trends Immunol"},{"key":"1811_CR107","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41416-024-02715-6","volume":"131","author":"JH Rannikko","year":"2024","unstructured":"Rannikko JH, Hollm\u00e9n M. Clinical landscape of macrophage-reprogramming cancer immunotherapies. Br J Cancer. 2024;131:627\u201340.","journal-title":"Br J Cancer"},{"key":"1811_CR108","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","volume":"31","author":"KA Reiss","year":"2025","unstructured":"Reiss KA, Angelos MG, Dees EC, Yuan Y, Ueno NT, Pohlmann PR, et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat Med. 2025;31:1171\u201382.","journal-title":"Nat Med"},{"key":"1811_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59326-9","volume":"16","author":"S Chen","year":"2025","unstructured":"Chen S, Wang Y, Dang J, Song N, Chen X, Wang J, et al. CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation. Nat Commun. 2025;16:4069.","journal-title":"Nat Commun"},{"key":"1811_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07267-4","volume":"15","author":"L Ziane-Chaouche","year":"2024","unstructured":"Ziane-Chaouche L, Raffo-Romero A, Hajjaji N, Kobeissy F, Pinheiro D, Aboulouard S, et al. Inhibition of furin in CAR macrophages directs them toward a proinflammatory phenotype and enhances their antitumor activities. Cell Death Dis. 2024;15:879.","journal-title":"Cell Death Dis"},{"key":"1811_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62506-2","volume":"16","author":"Y Xiao","year":"2025","unstructured":"Xiao Y, Zhu T, Chen Z, Huang X. Lung metastasis and recurrence is mitigated by CAR macrophages, in-situ-generated from mRNA delivered by small extracellular vesicles. Nat Commun. 2025;16:7166.","journal-title":"Nat Commun"},{"key":"1811_CR112","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2426724122","volume":"122","author":"L Zhou","year":"2025","unstructured":"Zhou L, Song Q, Zhang X, Cao M, Xue D, Sun Y, et al. In vivo generation of CAR macrophages via the enucleated mesenchymal stem cell delivery system for glioblastoma therapy. Proc Natl Acad Sci USA. 2025;122:e2426724122.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1811_CR113","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142:699\u2013713.","journal-title":"Cell"},{"key":"1811_CR114","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","volume":"182","author":"M Molgora","year":"2020","unstructured":"Molgora M, Esaulova E, Vermi W, Hou J, Chen Y, Luo J, et al. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy. Cell. 2020;182:886\u2013900.e17.","journal-title":"Cell"},{"key":"1811_CR115","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","volume":"572","author":"AA Barkal","year":"2019","unstructured":"Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572:392\u20136.","journal-title":"Nature"},{"key":"1811_CR116","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature19834","volume":"539","author":"MM Kaneda","year":"2016","unstructured":"Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, et al. PI3K\u03b3 is a molecular switch that controls immune suppression. Nature. 2016;539:437\u201342.","journal-title":"Nature"},{"key":"1811_CR117","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331:1612\u20136.","journal-title":"Science"},{"key":"1811_CR118","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1200\/JCO.18.02018","volume":"37","author":"BI Sikic","year":"2019","unstructured":"Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, et al. First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol. 2019;37:946\u201353.","journal-title":"J Clin Oncol"},{"key":"1811_CR119","doi-asserted-by":"publisher","first-page":"e863","DOI":"10.1002\/onco.13629","volume":"26","author":"JH Lewis","year":"2021","unstructured":"Lewis JH, Gelderblom H, van de Sande M, Stacchiotti S, Healey JH, Tap WD, et al. Pexidartinib long-term hepatic safety profile in patients with tenosynovial giant cell tumors. Oncologist. 2021;26:e863\u201373.","journal-title":"Oncologist"},{"key":"1811_CR120","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200377","volume":"217","author":"T Laskowski","year":"2020","unstructured":"Laskowski T, Rezvani K. Adoptive cell therapy: living drugs against cancer. J Exp Med. 2020;217:e20200377.","journal-title":"J Exp Med"},{"key":"1811_CR121","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/ejh.14074","volume":"112","author":"M Ho","year":"2024","unstructured":"Ho M, Zanwar S, Paludo J. Chimeric antigen receptor T-cell therapy in hematologic malignancies: successes, challenges, and opportunities. Eur J Haematol. 2024;112:197\u2013210.","journal-title":"Eur J Haematol"},{"key":"1811_CR122","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3389\/fonc.2019.00196","volume":"9","author":"S Patel","year":"2019","unstructured":"Patel S, Burga RA, Powell AB, Chorvinsky EA, Hoq N, McCormack SE, et al. Beyond CAR T cells: other cell-based immunotherapeutic strategies against cancer. Front Oncol. 2019;9:196.","journal-title":"Front Oncol"},{"key":"1811_CR123","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3390\/cancers13040743","volume":"13","author":"A Titov","year":"2021","unstructured":"Titov A, Zmievskaya E, Ganeeva I, Valiullina A, Petukhov A, Rakhmatullina A, et al. Adoptive immunotherapy beyond CAR T-cells. Cancers (Basel). 2021;13:743.","journal-title":"Cancers (Basel)"},{"key":"1811_CR124","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol. 2024;21:47\u201366.","journal-title":"Nat Rev Clin Oncol"},{"key":"1811_CR125","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230903","volume":"221","author":"M Ayala Ceja","year":"2024","unstructured":"Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: major process parameters and next-generation strategies. J Exp Med. 2024;221:e20230903.","journal-title":"J Exp Med"},{"key":"1811_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101250","volume":"32","author":"J Dias","year":"2024","unstructured":"Dias J, Garcia J, Agliardi G, Roddie C. CAR-T cell manufacturing landscape-Lessons from the past decade and considerations for early clinical development. Mol Ther Methods Clin Dev. 2024;32:101250.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1811_CR127","doi-asserted-by":"publisher","first-page":"e004185","DOI":"10.1136\/jitc-2021-004185","volume":"10","author":"RC Abbott","year":"2022","unstructured":"Abbott RC, Hughes-Parry HE, Jenkins MR. To go or not to go? Biological logic gating engineered T cells. J Immunother Cancer. 2022;10:e004185.","journal-title":"J Immunother Cancer"},{"key":"1811_CR128","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38:473\u201388.","journal-title":"Cancer Cell"},{"key":"1811_CR129","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03442-3","volume":"20","author":"T Kouro","year":"2022","unstructured":"Kouro T, Himuro H, Sasada T. Exhaustion of CAR T cells: potential causes and solutions. J Transl Med. 2022;20:239.","journal-title":"J Transl Med"},{"key":"1811_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2024.101566","volume":"37","author":"S Chen","year":"2024","unstructured":"Chen S, van den Brink MRM. Allogeneic \u201cOff-the-Shelf\u201d CAR T cells: challenges and advances. Best Pr Res Clin Haematol. 2024;37:101566.","journal-title":"Best Pr Res Clin Haematol"},{"key":"1811_CR131","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11899-019-00528-6","volume":"14","author":"A Nianias","year":"2019","unstructured":"Nianias A, Themeli M. Induced pluripotent stem cell (iPSC)-derived lymphocytes for adoptive cell immunotherapy: recent advances and challenges. Curr Hematol Malig Rep. 2019;14:261\u20138.","journal-title":"Curr Hematol Malig Rep"},{"key":"1811_CR132","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N, Adusumilli PS. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 2019;36:471\u201382.","journal-title":"Cancer Cell"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01811-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01811-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01811-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:03:00Z","timestamp":1787043780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01811-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":132,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1811"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01811-y","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}